| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Calcitriol Derivative targets the vitamin D receptor (VDR), a nuclear receptor that regulates gene expression. It binds VDR with high affinity and activates VDR-mediated transcription. This regulates genes involved in calcium homeostasis, cell proliferation, differentiation, and immune function. The 3-propionitrile ether modification may alter its pharmacokinetic properties and reduce calcemic activity compared to calcitriol. It is an agonist of VDR.
|
|---|---|
| ln Vitro |
In vitro, Calcitriol Derivative binds VDR and activates VDR-responsive reporter genes in cells expressing VDR. It inhibits the proliferation of various cell types, including cancer cells and keratinocytes. It induces differentiation of cancer cells. It may have reduced calcemic activity compared to calcitriol. Exact IC50 values vary by assay and cell type. It is used as a research tool for studying VDR biology.
|
| ln Vivo |
No independent in vivo efficacy data are widely reported for Calcitriol Derivative. As a research compound, it is primarily used for in vitro and cellular studies. In vivo characterization, including pharmacokinetics, efficacy, and toxicity, has not been extensively reported in published literature. Its therapeutic potential in animal models remains to be determined. It is a tool compound for studying VDR signaling.
|
| Enzyme Assay |
For non-cell receptor binding assays, recombinant VDR ligand-binding domain is incubated with radiolabeled calcitriol and Calcitriol Derivative at serial dilutions. Bound radioligand is separated by charcoal adsorption or filtration. IC50 values are calculated from competition curves. VDR-mediated transcription is measured by luciferase reporter assay using purified VDR and coactivators.
|
| Cell Assay |
In cell assays, VDR-expressing cells (e.g., keratinocytes, cancer cell lines) are treated with Calcitriol Derivative. Cell proliferation is measured by MTT or BrdU incorporation. Differentiation markers are measured by Western blot or qPCR. VDR target gene expression (e.g., CYP24A1) is measured by qPCR. Luciferase reporter assays measure VDR transcriptional activity.
|
| Animal Protocol |
No established in vivo animal protocol exists for Calcitriol Derivative. If in vivo studies were conducted, the compound would be formulated in DMSO/PEG/saline or corn oil and administered intraperitoneally or orally. Endpoints would include pharmacokinetic parameters, VDR target gene expression in tissues, and efficacy in hyperproliferative disease models. Serum calcium levels would be monitored for toxicity.
|
| References |
|
| Molecular Formula |
C30H47NO3
|
|---|---|
| Molecular Weight |
469.6991
|
| Exact Mass |
469.355
|
| CAS # |
2070009-24-2
|
| Related CAS # |
Calcitriol;32222-06-3
|
| PubChem CID |
66577070
|
| Appearance |
White to off-white solid powder
|
| LogP |
5.3
|
| tPSA |
73.5
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
34
|
| Complexity |
831
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
O([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])C([H])([H])C([H])([H])[C@@]([H])(C([H])([H])[H])[C@@]1([H])C([H])([H])C([H])([H])[C@@]2([H])/C(=C(\[H])/C(/[H])=C3\C(=C([H])[H])[C@]([H])(C([H])([H])[C@@]([H])(C\3([H])[H])OC([H])([H])C([H])([H])C#N)O[H])/C([H])([H])C([H])([H])C([H])([H])[C@]12C([H])([H])[H]
|
| InChi Key |
JEXMJWGETRFCMK-MSCDRTKFSA-N
|
| InChi Code |
InChI=1S/C30H47NO3/c1-21(9-6-15-29(3,4)33)26-13-14-27-23(10-7-16-30(26,27)5)11-12-24-19-25(34-18-8-17-31)20-28(32)22(24)2/h11-12,21,25-28,32-33H,2,6-10,13-16,18-20H2,1,3-5H3/b23-11+,24-12-/t21-,25-,26-,27+,28+,30-/m1/s1
|
| Chemical Name |
3-[(1R,3Z,5S)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-5-hydroxy-4-methylidenecyclohexyl]oxypropanenitrile
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1290 mL | 10.6451 mL | 21.2902 mL | |
| 5 mM | 0.4258 mL | 2.1290 mL | 4.2580 mL | |
| 10 mM | 0.2129 mL | 1.0645 mL | 2.1290 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.